Mediwheel <wellness@mediwheel.in>

Thu 3/28/2024 2:30 PM

To:PHC [MH-Ghaziabad] < phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in < customercare@mediwheel.in >



011-41195959

Hi Manipal Hospital,

The following booking has been confirmed. It is requested to honor the said booking & provide priority services to our client

Hospital

Package Name

: Mediwheel Full Body Health Checkup Female Above 40

Patient Package

Name

: Mediwheel Full Body Health Checkup Female Above 40

Hospital

NH-24, Hapur Road, Oppo. Bahmeta Village, Near Lancraft Golf Links

Address

Aparment

Contact Details : 9654018698

Appointment

Date

: 29-03-2024

Confirmation

Status

: Booking Confirmed

Preferred Time : 9:00am

Member II	Mormation	
Booked Member Name	Age	Gender
Sangeeta	40 year	Female

We request you to facilitate the employee on priority.

Thanks, Mediwheel Team Please Download Mediwheel App





You have received this mail because your e-mail ID is registered with Arcofemi Healthcare Limited This is a system-generated e-mail please don't reply to this message.

Please visit to our Terms & Conditions for more information. Click here to unsubscribe.



भारत सरकार - GOVERNMENT OF BOTA



संगीना Sangeeta जन्म तिथि/ DOB: 01/01/1984 सित्ता / FEIVIALE



8206 0309 7026 -आम आदमी का अधिकार



भारतीय विशिष्ट पहचान प्राधिकरण UNIONE DESTRICATION AUTHORITY OF PADIA

पता: WO: बोबी, 577, शाहपूर Ghandad, Grandad. Charded - 201902 साजियादाद.

WO Bobi, 577, dissipar Basebeta-4.

Address.

उत्तर प्रदेश - 201002

8206 0309 7026

-Aam Admi ka Adhikar





Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MRS SANGEETA

Registration No

: MH011808207

Patient Episode

: H18000002018

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 17:00

Age

40 Yr(s) Sex :Female

Lab No

202403004303

Collection Date:

29 Mar 2024 17:00

Reporting Date:

30 Mar 2024 10:29

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

PLASMA GLUCOSE

Specimen:Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

102.0

mg/dl

[80.0-140.0]

Method: Hexokinase

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying,

brisk glucose absorption , post exercise

Page 2 of 2

----END OF REPORT-





Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

: MRS SANGEETA : MH011808207

Registration No : H18000002018 Patient Episode

Referred By **Receiving Date**

Name

: HEALTH CHECK MGD

: 29 Mar 2024 17:00

Age

40 Yr(s) Sex :Female

Lab No

202403004301

Collection Date:

29 Mar 2024 17:00

Reporting Date:

30 Mar 2024 10:37

CLINICAL PATHOLOGY

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance

SLIGHTLY TURBID 7.0

(4.6 - 8.0)

Reaction[pH] Specific Gravity

1.005

(1.003 - 1.035)

CHEMICAL EXAMINATION

Protein/Albumin

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies Urobilinogen

Negative

(NEGATIVE) (NORMAL)

(0-5/hpf)

(0-2/hpf)

Normal

MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells

20-30 /hpf

NIL

RBC Epithelial Cells

25-30

/hpf

CASTS

NIL

NIL

Crystals

Bacteria

NIL

OTHERS

NIL

Page 1 of 2

----END OF REPORT----





Name

MRS SANGEETA

MH011808207

Registration No Patient Episode

H18000002018

Referred By

HEALTH CHECK MGD

Receiving Date

29 Mar 2024 11:40

Age

40 Yr(s) Sex: Female

Lab No

202403004301

Collection Date:

29 Mar 2024 11:40

Reporting Date:

29 Mar 2024 16:35

BLOOD BANK

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

This report is subject to the towns are

Blood Group & Rh typing

O Rh(D) Positive

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page 1 of 1

NOTE:

- Abnormal Values

-----END OF REPORT-----

Name

: MRS SANGEETA

Age

40 Yr(s) Sex :Female

Registration No

: MH011808207

Lab No

202403004301

Patient Episode

: H18000002018

Collection Date:

29 Mar 2024 11:40

Referred By

: HEALTH CHECK MGD

Reporting Date:

30 Mar 2024 10:25

Receiving Date

29 Mar 2024 11:40

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

THYROID PROFILE, Serum

[0.610 - 1.630]

T3 - Triiodothyronine (ELFA)

ng/ml 1.220

[4.680-9.360]

T4 - Thyroxine (ELFA)

5.710 ug/dl

Thyroid Stimulating Hormone

7,470 # µIU/mL

[0.250-5.000]

NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page 1 of 1

NOTE:

- Abnormal Values

----END OF REPORT----





Name

: MRS SANGEETA

Registration No

: MH011808207

Patient Episode

: H18000002018

Referred By

: HEALTH CHECK MGD

Receiving Date

TERRE

: 29 Mar 2024 11:40

Age

40 Yr(s) Sex :Female

Lab No

202403004301

Collection Date:

29 Mar 2024 11:40

Reporting Date:

29 Mar 2024 14:26

HAEMATOLOGY

TEST	RESULT	UNIT BIOLOGIC	CAL REFERENCE INTERVAL	
COMPLETE BLOOD COUNT (AUTOMAT	TED)	SPECIMEN-EDTA Whole	Blood	
RBC COUNT (IMPEDENCE) HEMOGLOBIN	4.40 11.6 #	millions/cumm	[3.80-4.80]	
Method:cyanide free SLS-color		g/dl	[12.0-15.0]	
HEMATOCRIT (CALCULATED) MCV (DERIVED)	37.1 84.3	% fL	[36.0-46.0] [83.0-101.0]	
MCH (CALCULATED) MCHC (CALCULATED)	26.4 31.3 #	pg g/dl	[25.0-32.0] [31.5-34.5]	
RDW CV% (DERIVED)	15.8 #	8	[11.6-14.0]	
Platelet count Method: Electrical Impedance	200	\times 10 3 cells/cumm	[150-410]	
MPV (DERIVED)	12.10	fL		
WBC COUNT(TC)(IMPEDENCE) DIFFERENTIAL COUNT	8.72	\times 10 3 cells/cumm	[4.00-10.00]	
(VCS TECHNOLOGY/MICROSCOPY)				
Neutrophils	67.0	ଚ	[40.0-80.0]	
Lymphocytes	25.0	ଚ	[20.0-40.0]	
Monocytes	6.0	8	[2.0-10.0]	
Eosinophils	2.0	00	[1,0-6.0]	
Basophils	0.0	90	[0.0-2.0]	
ESR	22.0 #	mm/1sthour	-0.0]	17.

Page 1 of 6





Name

: MRS SANGEETA

Registration No

: MH011808207

Patient Episode

: H18000002018

Referred By Receiving Date

TEROTE

: HEALTH CHECK MGD

: 29 Mar 2024 11:40

Age

40 Yr(s) Sex :Female

Lab No

202403004301

Collection Date:

29 Mar 2024 11:40

Reporting Date:

29 Mar 2024 13:54

BIOCHEMISTRY

Serum LIPID PROFILE Serum TOTAL CHOLESTEROL 167 mg/dl [<200]	
Serum TOTAL CHOLESTEROL 167 mg/dl	
Method:Oxidase, esterase, peroxide Moderate ris	sk:200-239
TRIGLYCERIDES (GPO/POD) 172 # mg/dl High risk: [<150] Borderline h)]
High: 200 Very high: Method: Enzymatic Immunoimhibition VLDL CHOLESTEROL (Calgulated)	- 499 >500 [5]
CHOLESTEROL (Calculated) 34 mg/dl [0-3 CHOLESTEROL, LDL, CALCULATED 81.0 mg/dl [<120.0 Near/	
William State Control of the Control	al rderline
LDL.CHOL/HDL.CHOL Ratio(Calculated) 1.6 <3 Optimal 3-4 Border >6 High Ri	line

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

Page 2 of 6





LABORATORY REPORT

Name

: MRS SANGEETA

Age

40 Yr(s) Sex :Female

Registration No

: MH011808207

Lab No

202403004301

Patient Episode

: H18000002018

Collection Date:

29 Mar 2024 11:40

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 13:54

Receiving Date

: 29 Mar 2024 11:40

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

KIDNEY PROFILE

Specimen: Serum			
UREA	13.2 #	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay			
BUN, BLOOD UREA NITROGEN	6.2 #	mg/dl	[8.0-20.0]
Method: Calculated			
CREATININE, SERUM	0.74	mg/dl	[0.70-1.20]
Method: Jaffe rate-IDMS Standardization			
URIC ACID	3.0 #	mg/dl	[4.0-8.5]
Method:uricase PAP			
SODIUM, SERUM	137.70	mmol/L	[136.00-144.00]
DOWN COTHIN OF DAIN		6 G000	
POTASSIUM, SERUM	3.80	mmol/L	[3.60-5.10]
SERUM CHLORIDE	102.3	mmol/L	[101.0-111.0]
Method: ISE Indirect			
OFF (1 1 1)			
eGFR (calculated)	100.2	ml/min/1.73sq.m	[>60.0]
Technical Note			

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

Page 3 of 6





LABORATORY REPORT

Name

: MRS SANGEETA

Age

40 Yr(s) Sex :Female

Registration No

: MH011808207

Lab No

202403004301

Patient Episode

: H18000002018

Collection Date:

29 Mar 2024 11:40

Referred By

: HEALTH CHECK MGD

Reporting Date:

29 Mar 2024 13:55

Receiving Date

: 29 Mar 2024 11:40

BIOCHEMISTRY

TEST	RESULT	UNIT	ВІ	OLOGICAL REFERENCE INTERVAL
LIVER FUNCTION TEST				
BILIRUBIN - TOTAL Method: D P D	0.56	÷	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.09		mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.47		mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	7.20		gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.28		g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	2.90		gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.47	*		[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	25.00		U/L	[0.00-40.00]
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	20.30		U/L	[14.00-54.00]
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	101.0 #		IU/L	[32.0-91.0]
GGT	17.0		U/L	[7.0-50.0]

Page 4 of 6





Name

: MRS SANGEETA

Registration No

: MH011808207

Patient Episode

: H18000002018

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 11:40

Age

40 Yr(s) Sex :Female

Lab No

202403004301

Collection Date :

29 Mar 2024 11:40

Reporting Date:

29 Mar 2024 13:55

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 5 of 6

-----END OF REPORT-----

Dr. Charu Agarwal Consultant Pathologist





Name

: MRS SANGEETA

: MH011808207

Registration No Patient Episode

: H18000002018

Referred By

: HEALTH CHECK MGD

Receiving Date

: 29 Mar 2024 11:40

Age

: 40 Yr(s) Sex : Female

Lab No

202403004302

Collection Date:

29 Mar 2024 11:40

Reporting Date: 29 Mar 2024 13:55

BIOCHEMISTRY

TEST

RESULT

BIOLOGICAL REFERENCE INTERVAL

GLUCOSE-Fasting

Specimen: Plasma

GLUCOSE, FASTING (F)

99.0

mg/dl

[70.0-110.0]

Method: Hexokinase

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases (e.g.galactosemia),

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 6 of 6

-----END OF REPORT-

This report is subject to the to-

Dr. Charu Agarwal **Consultant Pathologist**





NAME	MRS, SANGEETA	STUDY DATE	29/03/2024 3:35PM
AGE / SEX	42 y / F	HOSPITAL NO.	MH011808207
ACCESSION NO.	R7144383	MODALITY	CR
REPORTED ON	29/03/2024 3:59PM	REFERRED BY	HEALTH CHECK MGD

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Bronchovascular markings appear prominent.

TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal.

HEART: There is cardiomegaly, RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Aortic knuckle calcification is seen. Rest normal.

THORACIC SPINE: Degenerative changes are seen in the dorsal spine.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

IMPRESSION:

Prominent bronchovascular markings in bilateral lung fields.

Cardiomegaly.

Degenerative changes seen in the dorsal spine.

Recommend clinical correlation.

Dr. Monica Shekhawat MBBS, DNB

CONSULTANT RADIOLOGIST

Maria.

*****End Of Report*****





NAME	MRS, SANGEETA	STUDY DATE	29/03/2024 3:01PM
AGE / SEX	42 y / F	HOSPITAL NO.	MH011808207
ACCESSION NO.	R7144384	MODALITY	US
REPORTED ON	29/03/2024 3:16PM	REFERRED BY	HEALTH CHECK MGD

USG ABDOMEN & PELVIS

FINDINGS

LIVER: appears enlarged in size (measures 156 mm) but normal in shape and shows diffuse increase in liver echotexture, in keeping with diffuse grade I fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 90 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 8.0 mm.

COMMON BILE DUCT: Appears normal in size and measures 3.3 mm.

IVC, HEPATIC VEINS: Normal. BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended, Wall thickness is normal and lumen is echofree, Rest normal,

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Bilateral kidneys are normal in size, shape and echotexture. Cortico-medullary differentiation is maintained. Rest normal.

Right Kidney: measures 93 x 37 mm. Left Kidney: measures 96 x 44 mm. PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged. FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest

UTERUS: Uterus is anteverted, normal in size (measures 83 x 45 x 30 mm), shape and echotexture.

Endometrium is thickened and measures 9.9 mm. Cervix appears normal.

OVARIES: Right ovary shows a well defined anechoic cystic lesion with no internal

septations/reticulations/calcifications/abnormal vascularity within and measuring 29 x 28 x 23 mm with volume ~ 10.2 cc. Findings suggest simple/physiological right ovarian cyst.

Left ovary is normal in size (measures 23 x 22 x 10 mm with volume 2.7 cc), shape and echotexture. Rest normal.

Bilateral adnexa is clear.

BOWEL: Visualized bowel loops appear normal.

IMPRESSION

- -Hepatomegaly with diffuse grade I fatty infiltration in liver.
- -Thickened endometrium.
- -Simple/physiological right ovarian cyst.

ADV: US-TVS with Doppler for better assessment of uterus and bilateral adnexa. Recommend clinical correlation.

Marica.






NAME	MRS, SANGEETA	STUDY DATE	29/03/2024 3:01PM
AGE / SEX	42 y / F	HOSPITAL NO.	MH011808207
ACCESSION NO.	R7144384	MODALITY	US
REPORTED ON	29/03/2024 3:16PM	REFERRED BY	HEALTH CHECK MGD

Dr. Monica Shekhawat MBBS, DNB CONSULTANT RADIOLOGIST

*****End Of Report*****

- ABNORMAL ECG -

Unconfirmed Diagnosis



manipalhospitals





Patient Name MRS SANGEETA

Location

: Ghaziabad

Age/Sex

: 40Year(s)/Female

Visit No

: V000000001-GHZB

MRN No

MH011808207

Order Date

: 29/03/2024

Ref. Doctor : DR BHUPENDRA SINGH

Report Date

: 29/03/2024

Protocol

: Bruce

MPHR

: 180BPM

Duration of exercise

: 5min 18sec

85% of MPHR

: 153BPM

Reason for termination

: THR achieved

Peak HR Achieved : 153BPM

Blood Pressure (mmHg) : Baseline BP : 120/80mmHg

% Target HR

: 85%

Peak BP

: 140/90mmHg

METS

: 7.0METS

STAGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
PRE- EXC.	0:00	101	120/80	Nil	No ST changes seen	Nil
STAGE 1	3:00	136	130/90	Nil	No ST changes seen	Nil
STAGE 2	2:18	153	140/90	Nil	Nil No ST changes seen	
RECOVERY	4:14	107	130/80	Nil	No ST changes seen	Nil

COMMENTS:

- No ST changes in base line ECG.
- No ST changes at peak stage.
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

IMPRESSION:

Treadmil test is negative for exercise induced reversible myocardial ischemia.

Dr. Bhupendra Singh

Sr. Consultant Cardiology

Dr. Abhishek Singh

MD, DM (CARDIOLOGY), FACC MD, DNB (CARDIOLOGY), MNAMS MD

Sr.Consultant Cardiology

Dr. Sudhanshu Mishra

Cardiology Registrar

Manipal Hospital, Ghaziabad

P: 0120-3535353

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017

P +91.80.4936.0300 F info@manihospitals.com www.manipalhospitals.com